• Something wrong with this record ?

Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer

I. Sedláková, J. Laco, K. Caltová, M. Červinka, J. Tošner, A. Řezáč, J. Špaček,

. 2015 ; 25 (2) : 236-243.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16000373

Grant support
NT14107 MZ0 CEP Register

OBJECTIVE: This study aimed to evaluate the correlation between the expressions of lung resistance protein (LRP), P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP)-1, MRP3, and MRP5 and histopathological parameters and clinical outcome, and to determine the predictive and prognostic value of these transport proteins in patients with ovarian cancer. METHODS: Tumor samples from 111 chemonaive patients with epithelial ovarian cancer who underwent primary surgery from 2006 to 2010 were immunohistochemically stained for LRP, Pgp, MRP1, MRP3, and MRP5 expressions. RESULTS: MRP1 expression was greater among patients with late disease than among patients with early stage ovarian cancer [International Federation of Gynecology and Obstetrics (FIGO) I + II, 71.6% (confidence interval, 60-100); FIGO III + IV, 83.6% (confidence interval, 100-100); P = 0.03]. The histological subtype correlated with the expressions of LRP, Pgp, MRP1, and MRP3. Relapse of disease during the next 24 months occurred more often among patients with higher Pgp and MRP1 than among patients with lower Pgp and MRP1 expressions. FIGO stage, histological type, debulking efficiency, strong Pgp expression, and strong MRP1 expression correlated significantly with shorter progression-free survival (log-rank test, P = 0.001, P = 0.004, P = 0.001, P = 0.051, and P = 0.046, respectively). FIGO stage, histological type, debulking efficiency, and strong MRP1 expression correlated with poor patient survival (log-rank test, P = 0.001, P = 0.042, P = 0.005, and P = 0.018, respectively). CONCLUSIONS: Pgp and MRP1 expressions were clinically significant in patients with ovarian cancer. Pgp and MRP1 may be reliable, independent predictive and prognostic factors regarding the clinical outcome of ovarian cancer. MRP3 is less important as a predictive and prognostic factor than MRP1 expression. MRP5 and LRP expressions were not applicable prognostic parameters regarding ovarian cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000373
003      
CZ-PrNML
005      
20200121083243.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/IGC.0000000000000354 $2 doi
035    __
$a (PubMed)25594141
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sedláková, Iva $u Department of Gynecology and Obstetrics, University Hospital Hradec Králové and Medical Faculty, Czech Republic. $7 xx0061816
245    10
$a Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer / $c I. Sedláková, J. Laco, K. Caltová, M. Červinka, J. Tošner, A. Řezáč, J. Špaček,
520    9_
$a OBJECTIVE: This study aimed to evaluate the correlation between the expressions of lung resistance protein (LRP), P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP)-1, MRP3, and MRP5 and histopathological parameters and clinical outcome, and to determine the predictive and prognostic value of these transport proteins in patients with ovarian cancer. METHODS: Tumor samples from 111 chemonaive patients with epithelial ovarian cancer who underwent primary surgery from 2006 to 2010 were immunohistochemically stained for LRP, Pgp, MRP1, MRP3, and MRP5 expressions. RESULTS: MRP1 expression was greater among patients with late disease than among patients with early stage ovarian cancer [International Federation of Gynecology and Obstetrics (FIGO) I + II, 71.6% (confidence interval, 60-100); FIGO III + IV, 83.6% (confidence interval, 100-100); P = 0.03]. The histological subtype correlated with the expressions of LRP, Pgp, MRP1, and MRP3. Relapse of disease during the next 24 months occurred more often among patients with higher Pgp and MRP1 than among patients with lower Pgp and MRP1 expressions. FIGO stage, histological type, debulking efficiency, strong Pgp expression, and strong MRP1 expression correlated significantly with shorter progression-free survival (log-rank test, P = 0.001, P = 0.004, P = 0.001, P = 0.051, and P = 0.046, respectively). FIGO stage, histological type, debulking efficiency, and strong MRP1 expression correlated with poor patient survival (log-rank test, P = 0.001, P = 0.042, P = 0.005, and P = 0.018, respectively). CONCLUSIONS: Pgp and MRP1 expressions were clinically significant in patients with ovarian cancer. Pgp and MRP1 may be reliable, independent predictive and prognostic factors regarding the clinical outcome of ovarian cancer. MRP3 is less important as a predictive and prognostic factor than MRP1 expression. MRP5 and LRP expressions were not applicable prognostic parameters regarding ovarian cancer.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    12
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a proteiny spojené s mnohočetnou rezistencí k lékům $x metabolismus $7 D027425
650    _2
$a nádory glandulární a epitelové $x farmakoterapie $x metabolismus $x mortalita $x patologie $7 D009375
650    _2
$a nádory vaječníků $x farmakoterapie $x metabolismus $x mortalita $x patologie $7 D010051
650    _2
$a P-glykoprotein $x metabolismus $7 D020168
650    _2
$a prognóza $7 D011379
650    _2
$a analýza přežití $7 D016019
650    _2
$a vault ribonucleoprotein particles $x metabolismus $7 D020394
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Laco, Jan, $d 1979- $7 xx0051050 $u Department of Pathology, University Hospital Hradec Králové, Czech Republic
700    1_
$a Caltová, Kateřina $7 xx0197111 $u Department of Medical Biology and Genetics, Medical Faculty Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Červinka, Miroslav, $d 1950- $7 nlk19990074194 $u Department of Medical Biology and Genetics, Medical Faculty Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Tošner, Jindřich, $d 1947- $7 jn19990209929 $u Department of Gynecology and Obstetrics, University Hospital Hradec Králové and Medical Faculty
700    1_
$a Řezáč, Adam $7 xx0143232 $u Department of Gynecology and Obstetrics, University Hospital Hradec Králové and Medical Faculty
700    1_
$a Špaček, Jiří, $d 1957- $7 xx0143233 $u Department of Gynecology and Obstetrics, University Hospital Hradec Králové and Medical Faculty
773    0_
$w MED00009896 $t International journal of gynecological cancer official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 25, č. 2 (2015), s. 236-243
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25594141 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20200121083620 $b ABA008
999    __
$a ok $b bmc $g 1102654 $s 924579
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 25 $c 2 $d 236-243 $i 1525-1438 $m International journal of gynecological cancer $n Int J Gynecol Cancer $x MED00009896
GRA    __
$a NT14107 $p MZ0
LZP    __
$a Pubmed-20160108

Find record

Citation metrics

Archiving options